Cholangiocarcinoma Market - Top Companies and Manufacturers

In the News

• Verismo Therapeutics, a clinical-stage CAR T company and pioneer of the novel KIR-CAR platform technology, announced that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110, an investigational new drug administered intravenously for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma, and ovarian cancer.
• AstraZeneca, a global pharmaceutical company, announced that Imfinzi (durvalumab), a human monoclonal antibody that binds to the PD-L1 protein, had been approved in the U.S. by the FDA for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).